The GenoType of Leronlimab Leads to the PhenoType of the Leronlimab Disease Pattern

Got to say, we have an amazing molecule on our hands.

Truly applicable in countless applications both because of its unmatched safety profile as well as because of its integration at the core of inflammatory disease making it the optimal and ultimate ImmunoModulator.

Leronlimab does one thing. It is a blockade of CCR5.

"The mechanism of action (“MOA”) of leronlimab has the potential to modulate the movement of T-cells to inflammatory sites*, which could be beneficial by* diminishing overactive inflammatory responses*. Leronlimab is a unique humanized monoclonal antibody. Leronlimab binds to the second extracellular loop and N-terminus of the CCR5 receptor, and due to its selectivity and target-specific mechanism of action,* it does not appear to activate the immune function of the CCR5 receptor through agonist activity. This apparent target specificity differentiates leronlimab from other CCR5 antagonists. Leronlimab is a competitive rather than allosteric inhibitor of the CCR5 receptor.**"

The only way to determine what happens when you block CCR5 is by testing it out to determine what Patterns emerge. You give it to an individual, a monkey or a mouse who is sick and then see what happens. You take measurements and record the results. You analyze the results, rinse and repeat to hopefully observe that it happens again to confirm the validity of your test, then compare the outcomes to placebo and to other treatments.

Previously, much of what CytoDyn itself was built upon was evidence gathered in an anecdotal manner, but evidence which was believed, handled and applied by both company and shareholder alike, in a seemingly appropriate manner, considered as credible evidence, fitting the narrative, a Private Interpretation of the data, although not quite scientific. That is partly the reason why, despite everything that is currently going for it, CytoDyn finds itself sitting where it does right now. It is partially a result of the Private Interpretation of anecdotal evidence instead of the Public Interpretation of Scientific Evidence. However, because of the entirety of the work/labor done to get the clinical hold lifted, much of that previous anecdotal evidence Privately Interpreted has been turned into scientific, validated and verifiable evidence soon to be Publicly Interpreted in coming published peer reviewed Journal Articles and Manuscripts already submitted.

Leronlimab has been tested in multiple indications and has been routinely found to be effective as a potential treatment in each.

"The CCR5 receptor has been identified as a potential therapeutic target in a variety of settings, including HIV, graft-versus-host disease (“GvHD”), MASH, Alzheimer’s disease, cancer metastasis, multiple sclerosis, traumatic brain injury, stroke recovery, and a variety of inflammatory conditions, including COVID-19. This could present the potential for multiple opportunities for leronlimab to provide benefit in a variety of clinical settings."

Despite what has been found in the public domain of research by Institutions, Universities, Researchers, Physicians, PhDs and Scientists, in the past, CytoDyn had placed emphasis on anecdotal evidence and evidence that was not verified in the normal scientific manner, using Good Clinical Practice Guidelines and that was one of CytoDyn problems that led to where they are today. But they have since corrected that mistake. Anecdotal evidence is not considered proof to the FDA and they do not violate that rule.

Anything that is found to be anecdotally important and evident of leronlimab's effectiveness must be put to test scientifically to gain the validated truth about its functionality. Its function has to line up with its mechanism of action and be tied together with related and similar diseases where the biomarkers and the related biomarkers of the new disease match in movement. The functionality needs to fit somehow, needs to match up with prior instances of related biomarkers, related cell types and/or proteins involved. The mechanism of CCR5 blockade and the connection to these variables needs to be intertwined with the prior knowledge of the interaction of CCR5 blockade in a related disease entity each and every time it is tested.

The Patterns created by the administration of leronlimab in every disease pathology all need to flow together. The effects of the drug on a patient inflicted by these inflammatory disease states need to resemble each other for it to be a valid mark of the drug effectiveness. An overview of all the various effects leronlimab had on an inflamed individual in any of the above mentioned disease states following the administration of leronlimab would result in a "Knowable" Pattern that leronlimab induces upon any such sick patient. The Leronlimab Pattern becomes visible with the review of the outcomes of these trials. The Patient's own words as to the effect leronlimab induced should be documented and recorded in the trial's outcomes and those words should become part of the leronlimab database.

The Leronlimab Pattern gives an indication/clue as to the function of the drug. The deeper reason for why the drug was created in the first place. A study of the disease, the environment, the situation and the overall result provides the Pattern of the drug and that gives rise to the Meaning behind the drug. This Pattern occurs with repeated use of the drug and can be seen by studying the resulted outcomes provided that the outcomes are consistent.

A LAW is established when sufficient scientific research tests the theory and proves itself over and over again, without fail, then it becomes LAW. Consistency. Theory > With Consistency > LAW. Evolution > Theory, does not lead to LAW because evolution doesn't continue to repeat anymore, so just a theory. Gravity >> LAW because it repeats. What goes up, always comes down.

What is Leronlimab's Law in general? CCR5 blockade = Reduced Inflammation.

What is Leronlimab's Law in HIV?

"In 26 clinical studies previously conducted, leronlimab was generally well tolerated.

1. In addition, there were no dose-limiting toxicities or patterns of drug-related toxicities observed during these trials.
2. We believe the results of these trials establish that leronlimab’s antiviral activity is
   1. potent
   2. rapid
   3. prolonged
   4. dose-dependent.
3. Because leronlimab’s MOA as a monoclonal antibody in HIV is a relatively new therapeutic approach, it provides a potentially advantageous method of suppressing the virus in treatment-experienced patients who have failed a prior HIV regimen and need new treatment options."

What is Leronlimab's Law in Cancer?

"Research has shown that CCR5 expression is increased in a number of solid tumors including breast, colon, prostate, and pancreatic cancer among others. Increased CCR5 expression has also been identified as an indicator of increased risk of progression in several cancers. Research has hypothesized that CCR5 may play a variety of roles in the progression of cancer. 

1. The first is that Leronlimab blocks the CCR5 receptor on cancer cells and potentially plays a role in preventing the migration and invasion of cells into the bloodstream, which may lead to the prevention of metastasis.

2. The second is that blocking the CCR5 receptor on a group of immunosuppressive immune cells known as Regulatory T cells (Tregs) could turn on anti-tumor fighting properties thereby restoring immune function.

3. A third observation is that blocking the interaction of CCR5 with a chemokine known as RANTES (also known as CCL5) has a potentially synergistic effect with chemotherapy in controlling cancer progression.

4. Fourth, animal studies revealed a significant decrease in angiogenesis or new blood vessel formation following administration of leronlimab. Such new blood vessel formation is critically important for the growth of tumors.

5. And lastly, it is hypothesized that leronlimab exerts an effect on tissue macrophages in the tumor microenvironment to repolarize these cells into anti-tumor fighting cells."

Laws can be created when the drug's use has been tested over and over. We take every instance of its use and examine it for outcome to arrive at a law, doing a study of the outcome in each distinct disease. Determine the context to see what develops every time the drug is used in that context. If there is consistency, then you have discovered the law of the drug in that disease. If there is no consistency, then there is no law. At that point, you only have a theory if that.

Initially, MASH was considered exploratory but today, it is becoming a Law as murine studies were added following the initial study to augment the exploratory study. The additional murine studies were conducted to build upon the Phase 2a Exploratory Study. Today, another two murine studies shall soon be concluding and shall soon confirm a Leronlimab Law in MASH or will only allow it to live as a theory. Results are due this month January, 2025.

*"*MASH Phase 2a Exploratory Study

The Company has reported clinical data from patients with MASH from the CDI-MASH01 trial which was designed as a multi-center Phase 2a study and was subsequently converted into an exploratory study to evaluate the dose, efficacy, and safety of leronlimab at 350 mg and 700 mg, versus placebo. ... All analyses performed are being treated as exploratory. "

When a Pattern is established, it becomes a template. That template is applied if the next version of the drug is to precisely correlate with an older version of the drug. If after testing the new drug version, there seems to be sufficient similarities in the outcomes of the tests in all the disease entities, then much of the tried and true outcomes of the original version become applicable to the new version of the drug. Eventually, when it is deemed and confirmed to be very similar, then, the Private Interpretation of the new drug is discarded for what is already known as truth (Public Interpretation using Scientific Validated Evidence) regarding the original drug, the first version of the drug which is the template drug. The overall truth Pattern of the outcome of the treatment with Leronlimab must remain consistent between the two versions of the drug.

*"*Pre-Clinical Development of Long-Acting CCR5 Antagonist

In March 2023, the Company entered into a joint development agreement with a third-party generative AI drug discovery and development company to develop one or more longer-acting molecules. The Company believes working with a partner with AI capabilities will result in the expedited development of a modified, longer-acting therapeutic, and could lead to greater acceptance by patients due to the requirement for less frequent injections. The services provided by the third party may yield extended intellectual property protection, thereby increasing the value of the Company’s patent portfolio. In December 2023, the Company received various iterations of potential long-acting therapeutics, on which the Company will be performing assays to determine the suitability and feasibility of the long-acting therapeutic candidates for further development.

If successful, such a modified therapeutic would require less frequent injections for patients on drug, furthering the convenience and overall marketability of the product. Working with a company with established AI-capabilities allows for a robust development path for this modified, longer-acting therapeutic for the Company. This joint development initiative remains in progress at this time and the Company will provide further updates when appropriate.**"

When the Pattern is appreciated, detected, measured, regardless of which drug is used, a message is revealed that the drug was administered. A detectable change in the patient may be observed by one means or another which is consistent with the Pattern of Leronlimab. There can not be a difference between regular leronlimab and long acting leronlimab in the Pattern it induces once administered aside from the duration of action of the effects of the drug.

This overall effect of the drug is built into both molecules, the original and the long acting. They have the exact same effect on the disease and on the patient aside from how long it acts for. The Patterns they create provide a solidarity, a unity, that is not achieved by other CCR5 blockades, that is not achieved by other anti-inflammatories, by other anti-virals, etc. Certainly the side effect profile alone remains unchallenged as well as the means of healing.

The Pattern/Effect of the drug gives an idea of the overall intention of its creation. The return back to a healthy body without any fluff, just a resolution of disease without the onset of the typical inflammatory response symptomology of the disease. How is all this described? Words spoken / uttered by the patient. The patient's own words need to be documented as to how they feel following the administration of the drug. A questionnaire maybe with multiple choice answers. Then the overall intention of the design of the drug may be discerned.

This intention never changes. It is the same across all disease patterns and has been greatly achievable in this molecule because CCR5 resides at the heart or at the core of the Immunoregulatory System. CCR5 modulates Immunity and the Inflammatory Cascade and that is precisely where leronlimab functions. Therefore, leronlimab is an Immunomodulator operating at CCR5. These diseases don't change.

Something attacks the body which induces the onset of a disruptive mechanism of disease which after leronlimab administration is then disrupted by CCR5 blockade that interferes with the disease mechanism of action which had depended upon normal CCR5 functionality to manifest. But, leronlimab interfered and then modulated CCR5 function to return back to human health instead of the previously intended disease state.

With much study, we can ascertain the mechanisms by which the modulation of CCR5 achieves the restoration of human health despite the virulence of the attack. Currently, there exists an encyclopedia of knowledge of the effects of CCR5 blockade on a large variety of human disease states. Much of the Science of Leronlimab has been performed by outside institutions, researchers, physicians and PhDs and much of it has been collected using an FDA approved CCR5 antagonist, Maraviroc and to review and understand the entirety of that work would be an immense undertaking. However, the investors at CytoDyn are very fortunate to have an individual available who essentially has collected that vast storehouse of knowledge and is capable of applying it towards new indications and who is willing to share that knowledge with us.

Ohm20 has written a vast number of short posts and articles on the Science of Leronlimab describing the effects of leronlimab administration in a huge variety of circumstances. He put these snippets of information into an unsearchable database and now would prefer to put that same storehouse of information into a subreddit which is a searchable database. Unfortunately, he somehow is blocked in Reddit from doing so. He needs somebody who is willing to be a moderator for him that would manage the subreddit page and keep out the scoffers and slanderers, but allow for his posts to be made. His posts will simply be a compilation of what he has already posted on Investor's Hangout, but when made inside a subreddit, his posts automatically become searchable.

Making Ohm's posts searchable is incredibly important in deciphering how leronlimab functions on a biochemical level. The biomarkers, the cell types, the proteins, the minerals, etc all play a part and the way they function/behave may / may not be affected by leronlimab administration in one disease but is / is not in another. It may be determined if one disease is similar to another disease or how leronlimab may or may not function in another disease. All the biopharma knowledge in every tested disease state related to CCR5 blockade is there, but it is currently scattered and somewhat disorganized. Searching allows for organization, separation, weeding out the unnecessary, etc. Everything is necessary, but not when you're only looking for one thing. Searching allows to grasp the intention of the drug and secrets of the drug which remain hidden until associated with another related disease. Searching Ohm's posts gives us a much greater understanding of the molecule. Ohm is willing to put his prior posts into this subreddit database but he needs the help of a willing moderator. Does anyone want to step up?

Our interpretation of the biochemical processes that leronlimab causes shall correlate / correspond with the patient outcomes, principles and results of each trial. The understanding of the biochemical reactions, the Leronlimab Genotype leads to the Leronlimab Pattern, the leronlimab Phenotype Principles. The Patterns refer to the biochemical reactions, the intention. The Phenotype Principles refer to the Genotype mindset intention. There is no deviation between these because the outcome is designed into the molecule.

When the Pattern is found, you know leronlimab is at work and it can be understood biochemically using Ohm's database. That makes our interpretation of what we see happening reliable. We need to look for the Patterns, the numbers, the measurements, the percentages, the effects. Look for those parameters upon which the treatment is built upon. Look for Patterns for truth, need to go back to the seed bed of trials, go back to the research already performed, otherwise, we lose the Patterns.

"If CytoDyn were to continue to pursue the COVID-19 indication, we believe that subgroup analyses from our previous trials may inform the design of future clinical trials investigating leronlimab for the treatment of COVID-19."

Making Ohm's posts searchable, we can verify our interpretations and the interpretations of other researchers because his posts contain the Genotypical biochemical patterns which later lead to the Phenotypical outcomes which follow the administration of leronlimab. It allows us to validate and confirm our understanding instead of blindly accepting / believing it.

The leronlimab Phenotypical Pattern is woven into the Genotypical BioChemical reactions is the evidence of the intention of the molecule. The drug cures. It heals without inducing any inflammatory response of the body. The treasures the drug uncovers are yet to be discovered. Those treasures are hidden in Ohm's posts. Making those posts searchable makes those treasures discoverable. Ohm accounts for the majority of all research papers on CCR5 blockade. In a multitude of ways, he understands and communicates the vastness of leronlimab's functionality biochemically. It's not Ohm we are looking at, it is the understanding of what happens when CCR5 is blocked when leronlimab is doing the blocking. We shall find that all of his writings point to one intention, but expressed bio-chemically. Patterns without fail. Consistency in his literal scientific writing woven into its function.

Would someone please reach out on Investors Hangout to Ohm and moderate a sub-reddit for him?

I would, but I can't.

Certainly, his posts may be made here at Livimmune if he so chooses, but I think he prefers that they not be included with any other posts aside from his own, so that means a separate sub-reddit account.

Thanks so much.